Bambusa’s lead candidate BBT001 is being investigated for dermatologic indications. Credit: kirisa99 via Getty Images. US-based startup Bambusa Therapeutics has secured $90m in Series A financing to ...

Bambusa Therapeutics has raised about $90 million to build out a pipeline of next-gen bispecific antibodies targeting immunological and inflammatory (I&I) conditions. New investor RA Capital ...

Bambusa Therapeutics raised around $90 million in a series A round Friday to drive the development of bispecific antibodies for immunological and inflammatory disorders. The Boston-based company was ...